Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies

• Type: Article in International Scientific Journal
• Date: 2014

Authors

J.A. Loureiro (Author) FEUP; Bárbara Gomes (Author) FEUP; M. A. N. Coelho (Author) FEUP; M. do Carmo Pereira (Author) FEUP; Sandra Rocha (Author) FEUP

Journal

Title: Nanomedicine

Vol. 9 No. 5

Pages: 709-722

ISSN: 1743-5889

Publisher: Future Medicine Ltd.

Indexing

ISI Web of Knowledge - 42 Citations

ISI Web of Science

Scopus - 53 Citations

Pubmed / Medline

Scientific classification

FOS: Engineering and technology

CORDIS: Technological sciences ; Health sciences

Associated Projects

PTDC/QUI-BIQ/118076/2010 - Liposomas funcionalizados com anticorpos para a doença de Alzheimer

Referência: PTDC/QUI-BIQ/102827/2008 - Concepção de péptidos fluorados para inibição da agregação do péptido beta-amilóide e avaliação da sua actividade biológica

Other information

Authenticus ID: P-009-H7Q

DOI: 10.2217/nnm.14.27

Abstract (EN): Development of therapeutics for brain disorders is one of the more difficult challenges to be overcome by the scientific community due to the inability of most molecules to cross the blood-brain barrier (BBB). Antibody-conjugated nanoparticles are drug carriers that can be used to target encapsulated drugs to the brain endothelial cells and have proven to be very promising. They significantly improve the accumulation of the drug in pathological sites and decrease the undesirable side effect of drugs in healthy tissues. We review the systems that have demonstrated promising results in crossing the BBB through receptor-mediated endocytic mechanisms for the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 14